Enliven Therapeutics Income Statement (2019-2026) | ELVN

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & Development (Quarter)
10.40M10.86M7.06M7.94M7.83M8.20M11.88M15.18M19.61M17.91M19.97M18.83M21.26M20.72M24.89M21.49M18.23M21.25M20.69M29.00M
Selling, General & Administrative (Quarter)
3.26M3.48M1.62M1.08M3.10M1.97M4.54M4.95M4.64M4.82M6.02M5.78M5.81M6.17M6.80M7.09M6.87M13.04M7.14M8.21M
Operating Expenses (Quarter)
13.66M14.33M8.68M9.02M10.93M10.16M16.42M20.13M24.25M22.73M25.99M24.60M27.07M26.90M31.69M28.58M25.10M34.28M27.82M37.21M
Operating Income (Quarter)
-13.66M-14.33M-8.68M-9.02M-10.93M-10.16M-16.42M-20.13M-24.25M-22.73M-25.99M-24.60M-27.07M-26.90M-31.69M-28.58M-25.10M-34.28M-27.82M-37.21M
EBIT (Quarter)
-13.66M-14.33M-8.68M-9.02M-10.93M-10.16M-16.42M-20.13M-24.25M-22.73M-25.99M-24.60M-27.07M-26.90M-31.69M-28.58M-25.10M-34.28M-27.82M-37.21M
Non-operating items
Other Non Operating Income (Quarter)
-0.02M-0.06M-0.06M-0.04M-0.01M0.01M-0.00M-0.00M-0.16M-0.05M-0.00M0.05M-0.01M
Non Operating Income (Quarter)
0.01M0.07M0.01M0.13M0.38M0.61M1.69M3.41M3.49M3.35M3.25M4.09M3.91M4.36M3.20M3.25M4.95M4.62M4.20M4.73M
Net income details
EBT (Quarter)
-13.91M-14.38M-8.90M-9.46M-11.20M-29.71M-16.44M-20.25M-24.67M-65.52M-26.07M-24.69M-27.15M-26.94M-31.78M-29.20M-25.61M-34.40M-27.93M-39.12M
Tax Provisions (Quarter)
0.23M-18.88M-21.77M
Profit After Tax (Quarter)
-13.65M-14.34M-8.67M-8.89M-10.55M-9.55M-14.72M-16.72M-20.80M-19.22M-22.74M-19.95M-23.16M-23.37M-28.54M-25.34M-20.15M-29.39M-24.34M-34.01M
Income from Non-Controlling Interests (Quarter)
-0.00M-0.01M-0.04M-0.11M-0.04M0.29M-0.19M-0.09M0.38M-0.19M-0.07M-0.16M0.40M0.11M-0.72M-1.52M
Income from Continuing Operations (Quarter)
-13.91M-14.38M-8.90M-9.46M-11.20M-29.71M-16.44M-20.25M-24.67M-65.52M-26.07M-24.92M-27.15M-26.94M-31.78M-29.20M-25.61M-34.40M-27.93M-39.12M
Consolidated Net Income (Quarter)
-13.91M-14.38M-8.90M-9.46M-11.20M-29.71M-16.44M-20.25M-24.67M-65.52M-26.07M-24.92M-27.15M-26.94M-31.78M-29.20M-25.61M-34.40M-27.93M-39.12M
Income towards Parent Company (Quarter)
-13.91M-14.38M-8.90M-9.46M-11.20M-29.71M-16.44M-20.25M-24.67M-65.52M-26.07M-24.92M-27.15M-26.94M-31.78M-29.20M-25.61M-34.40M-27.93M-39.12M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-13.91M-14.38M-8.90M-9.46M-11.20M-29.71M-16.44M-20.25M-24.67M-65.52M-26.07M-24.92M-27.15M-26.94M-31.78M-29.20M-25.61M-34.40M-27.93M-39.12M
Additional items
EPS (Basic) (Quarter)
-2.24-2.66-1.35-1.44-1.70-4.52-0.89-0.49-0.60-1.84-0.62-0.52-0.56-0.57-0.63-0.56-0.41-0.61-0.44-0.59
EPS (Diluted) (Quarter)
-3.14-2.66-3.09-1.44-1.70-4.50-0.89-0.49-0.60-1.84-0.62-0.52-0.56-0.57-0.63-0.56-0.41-0.61-0.44-0.59
Shares Outstanding (Quarter)
6.22M5.42M6.57M6.57M6.57M6.57M18.51M40.96M41.03M35.55M42.05M48.08M48.27M47.07M50.05M52.11M62.09M56.66M62.80M66.17M
Shares Outstanding (Diluted) (Quarter)
4.43M5.42M2.88M6.57M6.57M6.60M18.51M40.96M41.03M35.55M42.05M48.08M48.27M47.07M50.05M52.11M62.09M56.66M62.80M66.17M
Shares Outstanding (Entity) (Quarter)
6.57M5.42M6.57M6.57M6.57M6.57M18.51M41.15M41.20M41.29M46.78M47.17M47.25M48.94M49.04M59.23M59.26M59.44M60.89M73.27M
EBITDA (Quarter)
-13.66M-14.33M-8.68M-9.02M-10.93M-10.16M-16.42M-20.13M-24.25M-22.73M-25.99M-24.60M-27.07M-26.90M-31.69M-28.58M-25.10M-34.28M-27.82M-37.21M
Interest Expenses (Quarter)
0.25M0.05M0.22M0.45M0.26M19.55M0.02M0.11M0.42M42.79M0.09M0.09M0.09M0.04M0.08M0.61M0.51M0.12M0.10M1.91M
Tax Rate (Quarter)
-0.94%70.07%63.29%